Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | HTR1D | P28221 | 4/20 | 0.48 |
| ▸ | HTR1B | P28222 | 4/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16717433 | 0.80 | ADORA1 (0.52) | POLBMEN1KMT2AGRM5KCNH2 | |
| SCHEMBL21195764 | 0.79 | GRM5 (0.54) | POLBGRM5KCNH2ALDH1A1NQO2 | |
| SCHEMBL28146671 | 0.79 | GRM5 (0.54) | POLBGRM5KCNH2ALDH1A1NQO2 | |
| SCHEMBL2242668 | 0.79 | GRM5 (0.54) | POLBGRM5KCNH2ALDH1A1NQO2 | |
| SCHEMBL21195641 | 0.79 | NCF1 (0.63) | GRM5KCNH2 | |
| SCHEMBL21217198 | 0.78 | NCF1 (0.53) | POLBMEN1KMT2AGRM5KCNH2 | |
| SCHEMBL27060737 | 0.78 | NCF1 (0.65) | POLBMEN1KMT2AGRM5KCNH2 | |
| SCHEMBL12132126 | 0.77 | ADORA1 (0.44) | POLBMEN1KMT2AALDH1A1ADORA1 | |
| SCHEMBL266444 | 0.77 | LMNA (0.64) | POLBMEN1KMT2AALDH1A1NQO2 | |
| SCHEMBL29877118 | 0.77 | LMNA (0.64) | POLBMEN1KMT2AALDH1A1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378242-B2 | Inhibiting CREB binding protein (CBP) | FORMA THERAPEUTICS, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-113784967-B | Compositions and methods for treating androgen receptor positive forms of cancer | 福马治疗股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3681885-B1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | FORMA THERAPEUTICS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | FORMA THERAPEUTICS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | FORMA THERAPEUTICS INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | FORMA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | FORMA THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| WO-2008110691-A1 | NOVEL TRICYCLIC DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2008-09-18 | — | — | WO | disclosed |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2008-08-07 | — | — | US | disclosed |
| EP-1953161-A1 | New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2008-08-06 | — | — | EP | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| EP-1406631-A4 | DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON | UNIV MICHIGAN (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1406631-A2 | DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-04-14 | — | — | EP | disclosed |
| WO-2002100350-A2 | DOPAMINE RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREON | THE REGENTS OF UNIVERSITY OF MICHIGAN (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016795-A1 | BROMODOMAIN INHIBITORS FOR ANDROGEN RECEPTOR-DRIVEN CANCERS | BRDT, AR, BRD4 | POLB 2188/4885MEN1 2133/4885KMT2A 115/4885 |
| US-20240150349-A1 | TETRAHYDRO-IMIDAZO QUINOLINE COMPOSITIONS AS CBP/P300 INHIBITORS | EP300, CREBBP, BRD3 | POLB 1080/4885MEN1 3328/4885KMT2A 390/4885 |
| US-12378242-B2 | Inhibiting CREB binding protein (CBP) | CREBBP, EP300, CREB1 | POLB 952/4885MEN1 3661/4885KMT2A 1264/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | POLB 1603/4885MEN1 1209/4885KMT2A 1961/4885 |
| US-11801243-B2 | Bromodomain inhibitors for androgen receptor-driven cancers | BRDT, AR, BRD4 | POLB 2188/4885MEN1 2133/4885KMT2A 115/4885 |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CASP3 | POLB 1510/4885MEN1 3381/4885KMT2A 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.